Clinical Trials Browser

OTHER × Mouth Neoplasms × Erlotinib Hydrochloride × Clear all

NCT06997068 2025-07-14

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Phase 2 Recruiting

Mouth Neoplasms

NCT00402779 2020-04-21

Erlotinib Prevention of Oral Cancer (EPOC)

Phase 3 Completed

303 enrolled 11 charts

Carcinoma in Situ, Mouth Neoplasms